Kuopio Lutetium-177 Study in Patients with PSMA-Positive Metastatic Prostate Cancer

This study is testing lutetium-177 PSMA therapy — a targeted radioactive treatment that homes in on prostate cancer cells using a protein called PSMA — in patients with metastatic castration-resistant prostate cancer (mCRPC) that has spread despite hormone therapy. **You may be eligible if...** - You are over 18 years old - You have histologically confirmed metastatic prostate adenocarcinoma - Your cancer continues to grow despite castration-level testosterone (castration-resistant) - Your PSMA PET scan shows PSMA-positive disease (the cancer is detectable by this scan) - You have received prior treatment with newer hormonal therapies (e.g., enzalutamide or abiraterone) **You may NOT be eligible if...** - Your cancer does not show PSMA expression on PET scan - Your kidney, liver, or bone marrow function is significantly impaired - You have received prior lutetium-177 PSMA treatment - You have rapidly progressing disease not suitable for this type of therapy Talk to your doctor to see if this trial is right for you.